A 3-year-old boy presents with infantile spasms and developmental delay. Skin examination reveals multiple hypomelanotic macules (ash-leaf spots) and facial angiofibromas. Brain MRI shows cortical tubers and a subependymal nodule near the foramen of Monro. Genetic testing confirms a deletion at the locus marked **A** in the diagram. Which of the following best explains why TSC2 mutations typically result in more severe disease manifestations compared to TSC1 mutations?
A. TSC2 mutations account for 85% of familial cases and are inherited in an autosomal recessive pattern
B. TSC2 is located on chromosome 16 while TSC1 is on chromosome 9, making TSC2 more susceptible to environmental mutagenesis
C. TSC2 deletions result in loss of the TSC1/TSC2 heterodimer's negative regulation of mTORC1, leading to unchecked cell growth and earlier, more extensive hamartoma formation
D. TSC2 encodes tuberin, which is the catalytic subunit of the mTORC1 complex and its loss causes unopposed mTOR signaling
Explanation
Why option 3 is correct
TSC2 (16p13.3) encodes tuberin, which forms a critical heterodimer with hamartin (TSC1 product). This complex functions as a negative regulator of mTORC1 signaling. When TSC2 is deleted or mutated, the heterodimer is disrupted, leading to loss of mTORC1 inhibition. This unleashes mTOR-driven cell growth, resulting in uncontrolled hamartoma formation across multiple organs. TSC2 mutations are clinically more severe than TSC1 mutations, manifesting with earlier seizure onset (often infantile spasms in infancy), higher tumor burden, more profound intellectual disability, and greater risk of life-threatening complications such as subependymal giant cell astrocytoma (SEGA) with obstructive hydrocephalus. This severity gradient is a hallmark feature recognized in the 2012 International TSC Consensus Criteria and Nelson Textbook of Pediatrics.
Why each distractor is wrong
Option 1: While TSC2 does encode tuberin, tuberin is NOT the catalytic subunit of mTORC1. Rather, it is a negative regulator (GAP protein) that inhibits mTORC1. This mischaracterizes the mechanism and would predict the opposite clinical effect.
Option 2: TSC is an autosomal dominant disorder, not recessive. Additionally, TSC2 mutations account for approximately 50% of cases (not 85%), and TSC1 mutations account for the other 50%. This option contains factually incorrect inheritance and epidemiology.
Option 4: While TSC2 is on chromosome 16p13.3 and TSC1 on chromosome 9q34, chromosomal location alone does not explain differential disease severity. The severity difference is mechanistic (related to the TSC1/TSC2 heterodimer function), not due to chromosomal position affecting mutagenesis rates.
High-YieldNEET PG
TSC2 mutations cause more severe disease than TSC1 because loss of the TSC1/TSC2 heterodimer unleashes mTORC1 signaling; TSC2 deletions are particularly aggressive, presenting with infantile spasms, high tumor burden, and profound developmental delay.
Nelson Textbook of Pediatrics 22e; 2012 TSC Consensus Criteria
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
